Literature DB >> 22107852

Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.

Fu-Shi Quan1, Richard W Compans, Sang-Moo Kang.   

Abstract

Oral vaccination would provide an easy and safe measure to prevent infectious diseases by facilitating mass immunization. We investigated the feasibility of oral vaccination with inactivated whole influenza virus (A/PR8/34). Oral vaccination of mice induced high levels of serum IgG and IgA antibodies specific to the homologous virus (A/PR8) as well as cross reactive to heterologous (A/California/04/09) and heterosubtypic viruses (A/Philippines/2/82). IgG1 isotype antibodies were found to be induced at significantly higher levels than IgG2a antibodies. These antibodies induced by oral vaccination exhibited hemagglutination inhibition activities. High levels of both IgG and IgA antibodies were induced in vagina and lungs. Mucosal IgA antibodies were also elicited in other sites including saliva, urine, and fecal samples. Orally vaccinated mice were completely protected against challenge with homologous or heterologous viruses, and partially protected against heterosubtypic virus. Importantly, high recall antibody secreting cell (ASC) responses were induced in spleen, indicating the generation of memory B cells by oral vaccination. The present study therefore presents new findings of cross-reactive antibodies at systemic and diverse mucosal sites, recall antibody responses, and cross-protective efficacies by oral vaccination, thus supporting a proof-of-concept that oral delivery of vaccines can be developed as an effective vaccination route.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22107852      PMCID: PMC5555299          DOI: 10.1016/j.vaccine.2011.11.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

Review 1.  Immunization without needles.

Authors:  Samir Mitragotri
Journal:  Nat Rev Immunol       Date:  2005-12       Impact factor: 53.106

2.  Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.

Authors:  S S Avtushenko; E M Sorokin; N Y Zoschenkova; N G Zacharova; A N Naichin
Journal:  J Biotechnol       Date:  1996-01-26       Impact factor: 3.307

3.  Oral influenza vaccination with live attenuated viruses. 2. Protective efficacy during a type A(H3N2) epidemic.

Authors:  F L Petrilli; P Crovari; P Cuneo-Crovari; G Badolati; R Canepa
Journal:  Boll Ist Sieroter Milan       Date:  1975-10-20

4.  Oral influenza vaccination with live attenuated viruses. 1. Acceptability, immunogenicity and transmissibility.

Authors:  F L Petrilli; P Crovari; P Cuneo-Crovari; G Badolati; R Canepa
Journal:  Boll Ist Sieroter Milan       Date:  1975-10-20

5.  Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Authors:  Rick A Bright; Donald M Carter; Shannon Daniluk; Franklin R Toapanta; Attiya Ahmad; Victor Gavrilov; Mike Massare; Peter Pushko; Nutan Mytle; Thomas Rowe; Gale Smith; Ted M Ross
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

6.  Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).

Authors:  M Conacher; J Alexander; J M Brewer
Journal:  Vaccine       Date:  2001-04-06       Impact factor: 3.641

7.  [Clinical and immunologic effects following oral immunization against influenza in children in day care and infection susceptible young children].

Authors:  S Wiersbitzky; R Bruns; E Seidel; H Tischner; J Broda; A Gocht; U Dorn; P Luther
Journal:  Padiatr Grenzgeb       Date:  1990

Review 8.  Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.

Authors:  R J Cox; K A Brokstad; P Ogra
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

9.  Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.

Authors:  Lucy A Perrone; Attiya Ahmad; Vic Veguilla; Xiuhua Lu; Gale Smith; Jacqueline M Katz; Peter Pushko; Terrence M Tumpey
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

10.  Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model.

Authors:  J-P Amorij; T A Westra; W L J Hinrichs; A Huckriede; H W Frijlink
Journal:  Vaccine       Date:  2007-11-09       Impact factor: 3.641

View more
  13 in total

1.  Immunogenicity and protection of oral influenza vaccines formulated into microparticles.

Authors:  Prathap Nagaraja Shastri; Min-Chul Kim; Fu-Shi Quan; Martin J D'Souza; Sang-Moo Kang
Journal:  J Pharm Sci       Date:  2012-06-18       Impact factor: 3.534

Review 2.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

3.  An alternative to airborne droplet transmission route of SARS-CoV-2, the feco-oral route, as a factor shaping COVID-19 pandemic.

Authors:  Ryszard Targoński; Aleksandra Gąsecka; Adrian Prowancki; Radosław Targoński
Journal:  Med Hypotheses       Date:  2022-07-01       Impact factor: 4.411

Review 4.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

5.  Immunogenicity of an electron beam inactivated Rhodococcus equi vaccine in neonatal foals.

Authors:  Angela I Bordin; Suresh D Pillai; Courtney Brake; Kaytee B Bagley; Jessica R Bourquin; Michelle Coleman; Fabiano N Oliveira; Waithaka Mwangi; David N McMurray; Charles C Love; Maria Julia B Felippe; Noah D Cohen
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

Review 6.  Prospects of HA-based universal influenza vaccine.

Authors:  Anwar M Hashem
Journal:  Biomed Res Int       Date:  2015-02-15       Impact factor: 3.411

Review 7.  Distal Consequences of Oral Inflammation.

Authors:  Joanne E Konkel; Conor O'Boyle; Siddharth Krishnan
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

8.  Influenza vaccine efficacy induced by orally administered recombinant baculoviruses.

Authors:  Swarnendu Basak; Hae-Ji Kang; Su-Hwa Lee; Ki-Back Chu; Eun-Kyung Moon; Fu-Shi Quan
Journal:  PLoS One       Date:  2020-05-27       Impact factor: 3.240

9.  Effects of administration of live or inactivated virulent Rhodococccus equi and age on the fecal microbiome of neonatal foals.

Authors:  Angela I Bordin; Jan S Suchodolski; Melissa E Markel; Kaytee B Weaver; Jörg M Steiner; Scot E Dowd; Suresh Pillai; Noah D Cohen
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

Review 10.  Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination.

Authors:  J A Otter; C Donskey; S Yezli; S Douthwaite; S D Goldenberg; D J Weber
Journal:  J Hosp Infect       Date:  2015-10-03       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.